Table 2. Population estimation and changes in clinical outcomes for GDMT and GDMT + Empagliflozin.
| Events (n) | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Total event | Annual Average | Total difference1, (%) | Annual difference2, (%) |
|---|---|---|---|---|---|---|---|---|---|
| Population ≥ 18 years | 24,935,385 | 25,184,739 | 25,436,586 | 25,690,952 | 25,947,862 | 127,195,524 | 25,439,104 | ||
| Incidence of HF | 209,457 | 211,552 | 213,667 | 215,804 | 217,962 | 1,068,442 | 213,688 | ||
| Guideline Directed Medical Therapy (GDMT) | |||||||||
| Cardiovascular death | 11,579 | 17,643 | 23,588 | 29,417 | 35,135 | 117,361 | 23,472 | ||
| Prevalence of HF | 381,824 | 581,797 | 777,821 | 970,037 | 1,158,582 | 3,870,061 | 774,012 | ||
| Diagnosed patients | 305,459 | 465,437 | 622,257 | 776,030 | 926,866 | 3,096,049 | 619,209 | ||
| Treated patients | 213,821 | 325,806 | 435,580 | 543,221 | 648,806 | 2,167,234 | 433,446 | ||
| HFrEF | 138,770 | 211,448 | 282,691 | 352,550 | 421,075 | 1,406,535 | 281,306 | ||
| HFrEF with DM | 80,487 | 122,640 | 163,961 | 204,479 | 244,224 | 815,790 | 163,158 | ||
| Adverse event | 5,939 | 9,049 | 12,099 | 15,089 | 18,022 | 60,199 | 12,039 | ||
| Cardiovascular death | 11,578 | 17,643 | 23,587 | 29,416 | 35,134 | 117,361 | 23,472 | ||
| HF hospitalisation | 22,184 | 33,803 | 45,192 | 56,360 | 67,315 | 224,857 | 44,971 | ||
| Renal composite outcome | 4,551 | 6,934 | 9,271 | 11,562 | 13,809 | 46,128 | 9,225 | ||
| Guideline Directed Medical Therapy (GDMT) + Empagliflozin | |||||||||
| Cardiovascular death | 11,494 | 17,453 | 23,253 | 29,007 | 34,654 | 115,862 | 23,172 | ||
| Prevalence of HF | 381,824 | 581,881 | 778,095 | 970,646 | 1,159,600 | 3,872,046 | 774,409 | ||
| Diagnosed patients | 305,459 | 465,505 | 622,476 | 776,517 | 927,680 | 3,097,637 | 619,527 | ||
| Treated patients | 213,821 | 325,853 | 435,733 | 543,562 | 649,376 | 2,168,346 | 433,670 | ||
| HF patients with LVEF≤40% | 138,770 | 211,479 | 282,791 | 352,771 | 421,445 | 1,407,256 | 281,451 | ||
| HF patients with LVEF≤40% and DM | 80,487 | 122,658 | 164,019 | 204,607 | 244,438 | 816,209 | 163,241 | ||
| Adverse event | 6,110 | 9,441 | 12,799 | 15,966 | 19,074 | 63,391 | 12,678 | 3,191 (5.3%) | 638 (1.06%) |
| Cardiovascular death | 11,494 | 17,453 | 23,253 | 29,007 | 34,654 | 115,862 | 23,172 | -1498 (-1.3%) | -299 (-0.26%) |
| HF hospitalisation | 21,499 | 32,241 | 42,415 | 52,911 | 63,211 | 212,278 | 42,455 | -12,578 (-5.6%) | -2,515 (1.12%) |
| Renal composite outcome | 4,336 | 6,445 | 8,400 | 10,479 | 12,519 | 42,183 | 8,436 | -3,945 (-8.6%) | -789 (-1.72%) |
1 Total difference is defined as the difference between GDMT and GDMT + Empagliflozin over the 5 years.
2 Annual difference is defined as the average of the total difference between GDMT and GDMT + Empagliflozin over the 5 years.